{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T22:29:34Z","timestamp":1793140174551,"version":"4.5.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,4,13]],"date-time":"2024-04-13T00:00:00Z","timestamp":1712966400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,4,13]],"date-time":"2024-04-13T00:00:00Z","timestamp":1712966400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Daiichi Sankyo Deutschland GmbH"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Patients with metastatic gastric cancer (mGC) have poor prognosis. This real-world study aimed to describe treatment regimens and survival of mGC patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective analysis was conducted using anonymized German claims data (AOK PLUS) covering a period from 2010 to 2021. The study population included newly diagnosed mGC cases identified from 2011 to 2020. The index date was defined as the first diagnosis of metastasis on or after gastric cancer diagnosis. Therapy regimens were identified based on inpatient and outpatient data, and subsequently stratified by line of treatment. Survival analyses were conducted using the Kaplan\u2013Meier method.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The cohort consisted of 5,278 mGC incident cases (mean age: 72.7\u00a0years; male: 61.9%). Nearly half of the incident cases received mGC-related treatment (49.8%). Treated patients were more often male, younger, and had fewer comorbidities compared to untreated patients. Of the 2,629 mGC patients who started the first line of treatment (1LOT), 32.8% switched to 2LOT, and 10.2% reached 3LOT. Longer survival time was observed among disease-specific treated cases compared with untreated cases (median real-world overall survival (rwOS): 12.7\u00a0months [95%CI 12.1 \u2013 13.3\u00a0months] vs. 3.7\u00a0months [95%CI 3.4 \u2013 4.0\u00a0months]).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Systemic therapy was not received in almost half of the mGC patients. In those patients, a very short median rwOS was observed. Treatment patterns were generally in line with the guideline recommendations, however, therapy switching rates and poor prognosis indicate high unmet needs also in the treated population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-024-12204-x","type":"journal-article","created":{"date-parts":[[2024,4,13]],"date-time":"2024-04-13T10:01:28Z","timestamp":1713002488000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Real-world evidence of treatment patterns and survival of metastatic gastric cancer patients in Germany"],"prefix":"10.1186","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5990-7534","authenticated-orcid":false,"given":"Jaime","family":"Luna","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5328-4332","authenticated-orcid":false,"given":"Nils","family":"Picker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Wilke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8930-5243","authenticated-orcid":false,"given":"Magnus","family":"Lutz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-7568-4330","authenticated-orcid":false,"given":"J\u00fcrgen","family":"Hess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8643-4170","authenticated-orcid":false,"given":"Bernhard","family":"M\u00f6rtl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1212-5516","authenticated-orcid":false,"given":"Yan","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thorsten Oliver","family":"G\u00f6tze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,13]]},"reference":[{"key":"12204_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209\u201349. https:\/\/doi.org\/10.3322\/caac.21660.","journal-title":"CA Cancer J Clin"},{"key":"12204_CR2","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1016\/S0140-6736(12)60919-2","volume":"380","author":"I Soerjomataram","year":"2012","unstructured":"Soerjomataram I, Lortet-Tieulent J, Parkin DM, Ferlay J, Mathers C, Forman D, et al. Global burden of cancer in 2008: a systematic analysis of disability-adjusted life-years in 12 world regions. Lancet. 2012;380:1840\u201350. https:\/\/doi.org\/10.1016\/S0140-6736(12)60919-2.","journal-title":"Lancet"},{"key":"12204_CR3","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.cgh.2019.07.045","volume":"18","author":"AP Thrift","year":"2020","unstructured":"Thrift AP, El-Serag HB. Burden of gastric cancer. Clin Gastroenterol Hepatol. 2020;18:534\u201342. https:\/\/doi.org\/10.1016\/j.cgh.2019.07.045.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"12204_CR4","doi-asserted-by":"publisher","first-page":"e033323","DOI":"10.1136\/bmjopen-2019-033323","volume":"10","author":"L Lou","year":"2020","unstructured":"Lou L, Wang L, Zhang Y, Chen G, Lin L, Jin X, et al. Sex difference in incidence of gastric cancer: an international comparative study based on the global burden of disease study 2017. BMJ Open. 2020;10:e033323. https:\/\/doi.org\/10.1136\/bmjopen-2019-033323.","journal-title":"BMJ Open"},{"key":"12204_CR5","doi-asserted-by":"publisher","first-page":"4012","DOI":"10.3390\/ijms21114012","volume":"21","author":"J Machlowska","year":"2020","unstructured":"Machlowska J, Baj J, Sitarz M, Maciejewski R, Sitarz R. Gastric cancer: epidemiology, risk factors, classification, genomic characteristics and treatment strategies. Int J Mol Sci. 2020;21:4012. https:\/\/doi.org\/10.3390\/ijms21114012.","journal-title":"Int J Mol Sci"},{"key":"12204_CR6","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1002\/ijc.31937","volume":"144","author":"J Ferlay","year":"2019","unstructured":"Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Pi\u00f1eros M, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019;144:1941\u201353. https:\/\/doi.org\/10.1002\/ijc.31937.","journal-title":"Int J Cancer"},{"key":"12204_CR7","unstructured":"Robert Koch Institute. Cancer in Germany 2017\/ 2018. 2022."},{"key":"12204_CR8","doi-asserted-by":"publisher","first-page":"52307","DOI":"10.18632\/oncotarget.10740","volume":"7","author":"M Riihim\u00e4ki","year":"2016","unstructured":"Riihim\u00e4ki M, Hemminki A, Sundquist K, Sundquist J, Hemminki K. Metastatic spread in patients with gastric cancer. Oncotarget. 2016;7:52307. https:\/\/doi.org\/10.18632\/oncotarget.10740.","journal-title":"Oncotarget"},{"key":"12204_CR9","unstructured":"Tumorregister M\u00fcnchen. \u00dcberleben ICD-10 C16: Magenkarzinom. 2022. https:\/\/www.tumorregister-muenchen.de\/facts\/surv\/sC16__G-ICD-10-C16-MagenkarzinomSurvival.pdf."},{"key":"12204_CR10","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/S0140-6736(11)61873-4","volume":"379","author":"Y-J Bang","year":"2012","unstructured":"Bang Y-J, Kim Y-W, Yang H-K, Chung HC, Park Y-K, Lee KH, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet. 2012;379:315\u201321. https:\/\/doi.org\/10.1016\/S0140-6736(11)61873-4.","journal-title":"Lancet"},{"key":"12204_CR11","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","volume":"376","author":"Y-J Bang","year":"2010","unstructured":"Bang Y-J, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687\u201397. https:\/\/doi.org\/10.1016\/S0140-6736(10)61121-X.","journal-title":"Lancet"},{"key":"12204_CR12","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/j.annonc.2022.07.004","volume":"33","author":"F Lordick","year":"2022","unstructured":"Lordick F, Carneiro F, Cascinu S, Fleitas T, Haustermans K, Piessen G, et al. Gastric cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33:1005\u201320. https:\/\/doi.org\/10.1016\/j.annonc.2022.07.004.","journal-title":"Ann Oncol"},{"key":"12204_CR13","doi-asserted-by":"publisher","first-page":"167","DOI":"10.6004\/jnccn.2022.0008","volume":"20","author":"JA Ajani","year":"2022","unstructured":"Ajani JA, D\u2019Amico TA, Bentrem DJ, Chao J, Cooke D, Corvera C, et al. Gastric Cancer, Version 2.2022, NCCN clinical practice guidelines in oncology. J Natl Comprehens Cancer Netw. 2022;20:167\u201392. https:\/\/doi.org\/10.6004\/jnccn.2022.0008.","journal-title":"J Natl Comprehens Cancer Netw"},{"key":"12204_CR14","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1016\/j.jclinepi.2004.03.012","volume":"57","author":"V Sundararajan","year":"2004","unstructured":"Sundararajan V, Henderson T, Perry C, Muggivan A, Quan H, Ghali WA. New ICD-10 version of the Charlson comorbidity index predicted in-hospital mortality. J Clin Epidemiol. 2004;57:1288\u201394. https:\/\/doi.org\/10.1016\/j.jclinepi.2004.03.012.","journal-title":"J Clin Epidemiol"},{"key":"12204_CR15","doi-asserted-by":"publisher","first-page":"e297","DOI":"10.1371\/journal.pmed.0040297","volume":"4","author":"JP Vandenbroucke","year":"2007","unstructured":"Vandenbroucke JP, von Elm E, Altman DG, G\u00f8tzsche PC, Mulrow CD, Pocock SJ, et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. PLoS Med. 2007;4:e297. https:\/\/doi.org\/10.1371\/journal.pmed.0040297.","journal-title":"PLoS Med"},{"key":"12204_CR16","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/j.zefq.2014.08.022","volume":"108","author":"E Swart","year":"2014","unstructured":"Swart E, Schmitt J. STandardized Reporting Of Secondary data Analyses (STROSA) - Vorschlag f\u00fcr ein Berichtsformat f\u00fcr Sekund\u00e4rdatenanalysen. Z Evid Fortbild Qual Gesundhwes. 2014;108:511\u20136. https:\/\/doi.org\/10.1016\/j.zefq.2014.08.022.","journal-title":"Z Evid Fortbild Qual Gesundhwes"},{"key":"12204_CR17","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1080\/14737140.2020.1781620","volume":"20","author":"K Harada","year":"2020","unstructured":"Harada K, Zhao M, Shanbhag N, Baba H, Ajani JA. Palliative care for advanced gastric cancer. Expert Rev Anticancer Ther. 2020;20:575\u201380. https:\/\/doi.org\/10.1080\/14737140.2020.1781620.","journal-title":"Expert Rev Anticancer Ther"},{"key":"12204_CR18","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.clcc.2019.09.001","volume":"19","author":"DT Le","year":"2020","unstructured":"Le DT, Ott PA, Korytowsky B, Le H, Le TK, Zhang Y, et al. Real-world treatment patterns and clinical outcomes across lines of therapy in patients with advanced\/metastatic gastric or gastroesophageal junction cancer. Clin Colorectal Cancer. 2020;19:32\u201338.e3. https:\/\/doi.org\/10.1016\/j.clcc.2019.09.001.","journal-title":"Clin Colorectal Cancer"},{"key":"12204_CR19","unstructured":"Servier Deutschland GmbH. Trifluridin\/Tipiracil (Lonsurf\u00ae). 2018."},{"key":"12204_CR20","unstructured":"Leitlinienprogramm Onkologie. S3 Leitlinie Magenkarzinom 2019."},{"key":"12204_CR21","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1186\/s12885-019-6294-9","volume":"19","author":"X Guo","year":"2019","unstructured":"Guo X, Zhao F, Ma X, Shen G, Ren D, Zheng F, et al. A comparison between triplet and doublet chemotherapy in improving the survival of patients with advanced gastric cancer: a systematic review and meta-analysis. BMC Cancer. 2019;19:1125. https:\/\/doi.org\/10.1186\/s12885-019-6294-9.","journal-title":"BMC Cancer"},{"key":"12204_CR22","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/s12876-020-01232-z","volume":"20","author":"D G\u00f3mez-Ulloa","year":"2020","unstructured":"G\u00f3mez-Ulloa D, Amonkar M, Kothari S, Cheung WY, Chau I, Zalcberg JR, et al. Real-world treatment patterns, healthcare resource use and clinical outcomes of patients receiving second line therapy for advanced or metastatic gastric cancer. BMC Gastroenterol. 2020;20:133. https:\/\/doi.org\/10.1186\/s12876-020-01232-z.","journal-title":"BMC Gastroenterol"},{"key":"12204_CR23","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/s12325-020-01567-9","volume":"38","author":"V Shankaran","year":"2021","unstructured":"Shankaran V, Xiao H, Bertwistle D, Zhang Y, You M, Abraham P, et al. A comparison of real-world treatment patterns and clinical outcomes in patients receiving first-line therapy for unresectable advanced gastric or gastroesophageal junction cancer versus esophageal adenocarcinomas. Adv Ther. 2021;38:707\u201320. https:\/\/doi.org\/10.1007\/s12325-020-01567-9.","journal-title":"Adv Ther"},{"key":"12204_CR24","doi-asserted-by":"publisher","first-page":"e0198544","DOI":"10.1371\/journal.pone.0198544","volume":"13","author":"IS Choi","year":"2018","unstructured":"Choi IS, Choi M, Lee JH, Kim JH, Suh KJ, Lee JY, et al. Treatment patterns and outcomes in patients with metastatic gastric cancer receiving third-line chemotherapy: as population-based outcomes study. PLoS ONE. 2018;13:e0198544. https:\/\/doi.org\/10.1371\/journal.pone.0198544.","journal-title":"PLoS ONE"},{"key":"12204_CR25","doi-asserted-by":"publisher","first-page":"2656","DOI":"10.1093\/annonc\/mds104","volume":"23","author":"YY Janjigian","year":"2012","unstructured":"Janjigian YY, Werner D, Pauligk C, Steinmetz K, Kelsen DP, J\u00e4ger E, et al. Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis. Ann Oncol. 2012;23:2656\u201362. https:\/\/doi.org\/10.1093\/annonc\/mds104.","journal-title":"Ann Oncol"},{"key":"12204_CR26","doi-asserted-by":"publisher","first-page":"77","DOI":"10.3978\/j.issn.2078-6891.2010.025","volume":"2","author":"D Yang","year":"2011","unstructured":"Yang D, Hendifar A, Lenz C, Togawa K, Lenz F, Lurje G, et al. Survival of metastatic gastric cancer: Significance of age, sex and race\/ethnicity. J Gastrointest Oncol. 2011;2:77\u201384. https:\/\/doi.org\/10.3978\/j.issn.2078-6891.2010.025.","journal-title":"J Gastrointest Oncol"},{"key":"12204_CR27","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1200\/JCO.20.02761","volume":"39","author":"I Haffner","year":"2021","unstructured":"Haffner I, Schierle K, Raim\u00fandez E, Geier B, Maier D, Hasenauer J, et al. HER2 expression, test deviations, and their impact on survival in metastatic gastric cancer: results from the prospective multicenter VARIANZ study. JCO. 2021;39:1468\u201378. https:\/\/doi.org\/10.1200\/JCO.20.02761.","journal-title":"JCO"},{"key":"12204_CR28","doi-asserted-by":"publisher","unstructured":"Aseafan M, Gad AM, Alshamsan B, Agha N, Alhanash A, Aljubran AH, et al. Outcomes and prognostic factors of metastatic gastric cancer: a single-center experience. Cureus 2022;14. https:\/\/doi.org\/10.7759\/cureus.28426.","DOI":"10.7759\/cureus.28426"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-024-12204-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-024-12204-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-024-12204-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,13]],"date-time":"2024-04-13T10:01:37Z","timestamp":1713002497000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-024-12204-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,13]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["12204"],"URL":"https:\/\/doi.org\/10.1186\/s12885-024-12204-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3890939\/v1","asserted-by":"object"}]},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,13]]},"assertion":[{"value":"23 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by a Scientific Committee, consisting of external experts, the cooperating sickness funds, the research sponsor, Cytel and IPAM. As the study analyzed retrospective anonymized claims data, the use of such data is not subject to ethics committee approval and no informed consent was required according to German laws (\u00a7 75 SGB X, Tenth Social Code Book). The work on the dataset conformed to all social security data protection requirements. The study followed all the dictates of the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"JL and NP participated in this study as staff members of Cytel; the work of IPAM and Cytel in this study was funded by Daiichi Sankyo Deutschland GmbH. ML, JH, BM participated in this study as staff members of Daiichi Sankyo Deutschland GmbH. YX participated in this study as staff member of Daiichi Sankyo. TG participated in this study as medical consultant. He is employed at Krankenhaus Nordwest gGmbH and holds a position at IKF- Institut f\u00fcr Klinische Krebsforschung GmbH. TG has provided consultation or served as a consultant for the following companies: Amgen, AstraZeneca, Bayer, BMS, Daiichi Sankyo, FoundationMedicine, Lilly, MCI, MSD Sharp & Dohme, Novartis, Roche, Sanofi Aventis, Servier, Deciphera, Boehringer-Ingelheim. TG has received honorarium from the following companies: Amgen, BMS, Lilly, MSD, Novartis, Sanofi Aventis, Servier, Roche, GSK. He has received funding for scientific investigations from the following sources: Lilly, AstraZeneca, Incyte, German Research Foundation (DFG), Gemeinsamer Bundesausschuss, German Cancer Aid (Deutsche Krebshilfe), Servier. TG has financial relationships with the following companies: Amgen, AstraZeneca, BMS, Lilly, Merck Serono, Roche, Sanofi Aventis, Servier, Pierre-Fabre.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"462"}}